[193 Pages Report] The Breast Biopsy Market size was estimated at USD 1.00 billion in 2023 and expected to reach USD 1.09 billion in 2024, at a CAGR 9.26% to reach USD 1.87 billion by 2030.
A breast biopsy is a medical procedure for removing a sample of breast tissue for testing. The pathologists analyze the tissue sample in the medical labs to provide an appropriate medical diagnosis. The prevalence of breast cancer among women worldwide and the inclination of patients toward early diagnosis and treatment of diseases raise the need for diagnostic solutions such as breast biopsy procedures. Governments across countries are implementing breast cancer awareness programs encouraging individuals to undergo screening tests and necessitating advanced breast biopsy procedures. However, the high cost of breast biopsy procedures and the possibility of infections associated with the biopsy needles may prevent patients from undergoing the breast biopsy procedure. In addition, the ongoing clinical trials and the advent of liquid biopsy are expected to improve the diagnosis and patient outcome for breast cancer treatment.
The surge in the incidence of breast cancer cases among women and the increase in the availability of advanced diagnostic treatment, coupled with the ongoing research on breast biopsy procedures, have increased the adoption of breast biopsy procedures among breast cancer patients in the Americas. The growing need for appropriate diagnosis and treatment for breast cancer to reduce breast cancer-related casualties and mitigate breast cancer risk factors are the factors that necessitate patients to avail of breast biopsy diagnostic procedures in the APAC region. The EMEA region has a significant need for breast biopsy diagnostic procedures owing to the increasing breast cancer awareness in older women and the rising need for improved diagnostic solutions for breast cancer. Additionally, significant investments by public and private organizations to expand the research on breast cancer are expected to improve and advance breast biopsy procedures.
The FPNV Positioning Matrix is pivotal in evaluating the Breast Biopsy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Breast Biopsy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology for Improving Personalized Cancer Care to Oncology Portfolio
Quest Diagnostics and Haystack Oncology reached a definitive agreement for Quest to acquire Haystack through an all-cash equity transaction. This strategic acquisition will allow Quest to capitalize on its expertise and scale in oncology, genomics, and pathology. The initial focus of the development efforts will be on MRD tests for colorectal, breast, and lung cancers. Following the completion of the acquisition, Quest plans to incorporate the MRD test developed by Haystack starting in 2024. [Published On: 2023-04-17]
Guardant Health Receives FDA Approval for Guardant360 CDx as Companion Diagnostic for Menarini Group’s ORSERDU for the Treatment of Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer
Guardant Health, Inc. obtained FDA approval for their liquid biopsy test, Guardant360 CDx, as a companion diagnostic to detect ESR1 mutations in advanced or metastatic breast cancer patients who may benefit from treatment with ORSERDU. Menarini Group takes pride in introducing the first treatment targeting ESR1 mutations found in up to 40% of ER+/HER2- advanced breast cancers. [Published On: 2023-01-30]
TransMed7, LLC Announces First Clinical Use of SpeedBird Breast Biopsy Devices for Commercial Launch
TransMed7 LLC announced the successful clinical implementation of the Sparrow device, a member of their SpeedBird family of vacuum-assisted Single Insertion/Multiple Collection (SIMC) Breast Biopsy devices. TransMed7 has designed and developed the SpeedBird and Concorde platforms to address and overcome issues associated with outdated biopsy devices that have been used for decades. [Published On: 2022-08-10]
The report delves into recent significant developments in the Breast Biopsy Market, highlighting leading vendors and their innovative profiles. These include Argon Medical, Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc, Biocept, Inc., Cook Group Incorporated, CooperSurgical, Inc., F. Hoffmann-La Roche Ltd., Fluxion Biosciences Inc., FUJIFILM Corporation, GE HealthCare, Guardant Health, Halma plc, Hologic, Inc., Illumina, Inc., INRAD, Inc., Iskus Health Ltd., Johnson & Johnson Services, Inc., Leica Biosystems Nussloch GmbH, Medtronic PLC, Merit Medical Systems, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific Inc., TransMed7, LLC, and Trivitron Healthcare.
This research report categorizes the Breast Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Product
- Assay Kits
- Biopsy Needles
- Biopsy Tables
- Guidance Systems
- Liquid Biopsy Instruments
- Localization Wires
- Type
- Liquid Breast Biopsy
- Circulating Tumor Cells
- Circulating Tumor DNA
- Needle Breast Biopsy
- Core Needle Biopsy
- Fine Needle Aspiration Biopsy
- Vacuum-Assisted Biopsy
- Open Surgical Breast Biopsy
- Excisional
- Incisional
- Liquid Breast Biopsy
- Guidance
- Image-Guided Biopsy
- Mammography-Guided Stereotactic Biopsy
- MRI Guided Biopsy
- Ultrasound-Guided Biopsy
- Liquid Biopsy
- Microarray-Based Biopsy
- NGS-Based Biopsy
- PCR-Based Biopsy
- Image-Guided Biopsy
- Application
- Early Cancer Screening
- Recurrence Monitoring
- Therapy Selection
- Treatment Monitoring
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Breast Biopsy Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Breast Biopsy Market?
- What are the technology trends and regulatory frameworks in the Breast Biopsy Market?
- What is the market share of the leading vendors in the Breast Biopsy Market?
- Which modes and strategic moves are suitable for entering the Breast Biopsy Market?
- Preface
- Research Methodology
- Executive Summary
- Market Overview
- Market Insights
- Breast Biopsy Market, by Product
- Breast Biopsy Market, by Type
- Breast Biopsy Market, by Guidance
- Breast Biopsy Market, by Application
- Americas Breast Biopsy Market
- Asia-Pacific Breast Biopsy Market
- Europe, Middle East & Africa Breast Biopsy Market
- Competitive Landscape
- Competitive Portfolio
- List of Figures [Total: 24]
- List of Tables [Total: 828]
- List of Companies Mentioned [Total: 25]
Liquid biopsy is a non-invasive diagnostic method that involves testing a patient's blood or other body fluids, such as urine or saliva, for the presence of cancer cells or tumor DNA. Liquid biopsy is currently used to diagnose cancers, such as lung and colon cancer, but its use for breast cancer is still in the early stages of development.
One of the benefits of liquid biopsy is that it may provide a less invasive alternative to traditional breast biopsies. A liquid biopsy could eliminate the need for a needle or incision, which can be uncomfortable for patients and sometimes lead to complications. In addition, a liquid biopsy could be a more accurate method for detecting early stages of cancer as it is easier to treat.
Clinical trials are underway to evaluate liquid biopsy's efficacy for breast cancer diagnosis. These studies involve comparing liquid biopsy results to traditional biopsy methods, such as needle and excisional biopsy. Some studies have shown promising results, with liquid biopsy detecting cancers that were missed by traditional biopsy methods.
Another promising development in breast biopsies is the use of ultrasound-guided biopsy. An ultrasound-guided biopsy involves using an ultrasound machine to guide the needle to the location of the suspicious tissue. This type of biopsy is less invasive than traditional biopsy methods and may be more comfortable for patients. In addition, ultrasound-guided biopsy is more accurate than mammography-guided biopsy in detecting breast cancer.
Breast cancer diagnosis and treatment continue to evolve with technological advancements and clinical research. Liquid and ultrasound-guided biopsies are just two promising developments in breast biopsy procedures that are expected to improve accuracy and reduce patient discomfort. As these methods continue to be studied and refined, they offer hope for more effective breast cancer diagnosis and treatment.
- How big is the Breast Biopsy Market?
- What is the Breast Biopsy Market growth?
- When do I get the report?
- In what format does this report get delivered to me?
- How long has 360iResearch been around?
- What if I have a question about your reports?
- Can I share this report with my team?
- Can I use your research in my presentation?